 its tubulin-inhibitor program for treating cancer. 

A federal district court has ruled in favor of 

 on its formulation patent for Seroquel (quetiapine fumarate) extended-release tablets. 

 has expanded its services in the academic research sector throughout the northeast United States. 

 have concluded a license agreement concerning the development and commercialization of the cutaneous T-cell lymphoma treatment bexarotene. 

 has agreed to purchase 10 million shares to increase its ownership in 

 board of directors has unanimously rejected 

 revised offer to acquire the company for $51 per share in cash. 

Pharmaceutical Research and Manufacturers of America

 Prescription Drug Abuse Reduction Policy Academy. 

 has named Lisa Cozza as vice-president of business development. 

 has appointed Michael J. Holston as chief ethics and compliance officer, effective June 25, 2012. He will succeed Richard S. Bowles, who plans to retire from the company. 

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.